Exhibit 62

From: Stephane Muuls [STEPHANE@fairdomain01.com]

Sent: Tuesday, September 10, 2002 5:21 PM

To: Jeffrey Tucker; Andres Piedrahita; Greg Bowes; Richard Landsberger; Sarah Stratton;

adam@fgguk.com; Philip Toub; Ron Thomann AOL

Cc: Carlos Garcia-Ordonez

Subject: ROC on trip to Switzerland from 08/27 to 09/03

Attachments: itinerary august 27.doc

Dear All,

Carlos and I came back from a trip to Zurich and Geneva were we introduced GMO and the Masters Fund. We also promoted FFTW. We have seen some new prospects and some of them were already exsisting clients. We are planning to go back to Geneva next month in order to follow up with new prospects. Also, please find attached the schedule of our trip. Here is a report on each of these meetings:

08/27/02 in Zurich:

Kurmann Partners

Jurg Kurmann: he is the Founding Partner of this firm is specialized in Private Equity. They used to be part of Remaco, a private equity firm, and are now independent. Their core business is the preparation and realization of ownership, financing and alliances transactions of companies on a national level as well as crossborder. They are also interested in Hedge Funds and this was our first contact with them. Apparently, he has an institutional client that is looking to invest in Hedge Funds. We did a presentation of FFTW, GMO and the Masters Funds. GMO might be interesting for his client. We will send him more info. about GMO.

BBVA

Rodolfo Ibañez

Luis Saenz de Andino is the new General Manager for Investment Management. Placed order as prelude to our visit of 500M FIF and wish to keep this fund on even allocation with FRM Uk,and ED&F Man, other variations of their preferred Multistrategy approach, in their managed accounts. On the point of FIF, they pointed to the need for monthly updates of the portfolio composition. Requested presentation to their Bankers and we offered to organize for mid to end of October to reinforce their knowledge of our funds and abilitate them to sell all FGG funds to the advisory clients. We spent some time speaking about the relationship. Besides that, we introduced the Master Fund and spoke about the Epsilon redemption.

Capital Stage

Berndt Samsinger: he is the CEO. Capital Stage AG along with its subsidiaries is a member of the German Association of Venture Capital Companies, is an official partner company of the Neuer Markt, is a participant on all German stock exchanges, and has been admitted to the XETRA trading system. The head office of Capital Stage is in Hamburg. They also operate at the locations Frankfurt, Düsseldorf, Glücksburg and Zurich. Around 100 staff are employed at the five locations. Their objective is to provide unsurpassed services and interdisciplinary expertise in order to bring their clients and portfolio companies long-term success. First contact

1

CONFIDENTIAL FGANW005076462

10-04330-lgb Doc 331-64 Filed 06/24/25 Entered 06/24/25 22:30:48 Exhibit 62 Pg 3 of 6

with them. They are launching a Nanotech Fund and hedge funds are not their core business, but he might know institutions that could show interest in our products. He is very well connected in Switzerland. We introduced FGG products.

Morgan Stanley

Mark Lavender is Head of Operations and we reviewed with him the contractual agreement, the operation issues and support the relationship. Mark Lavender shared with us the recent reorganization carried out and strongly recommended we pursue business besides their sales ofices as we have been doing in Geneva & Zurich. Also in London through Simon Brewer,newly appointed Head of European Asset Mgnt& Oscar Vermeulen, encharged with "New Open Architecture Program". Both names I have since passed them on to Adam Horne for follow up. According to Mark their effort with RMF has not received much support from the bankers, which leads to the assumption it must not be performing very well. We also need to investigate what's up with this fund, help our cause.

08/28/02 in Geneva:

Deutsche Bank

Gary Tiernan is a colleague of Steve Miller and is Chief of Alternative Investments for Europe. We supported the investment process that we are trying to achieve in New York and introduced GMO. Gary Tiernan confirmed the departure from the Bank of Claudio Beller with whom, I had initiated the contact in 1999. Saying Claudio would resurface surely at another institution so we need to keep our eyes open. Fortunately the rest of the team is intact, for the moment. Gary was uncomittal but very interested in hearing the latest nuinsances at FGG, and values the relationship. so believe the call was worthwhile for good will if nothing else as confirmed the Direct Advantage Program, investment decisions are made in NY.

Morgan Stanley

The group we visited was reduced to two bankers due to the holidays, ... Nonetheless it was a worthwhile meeting while unless it had a bitter sweet taste, as many bankers have been fired primarily the Middle East team, and we have received some FIF,redemptions and expressions of concern, the two showed interest in GMO and the Masters Fund: none have come back to us for pure Sentry, as assume are overweight with us and Kingate. They made no mention of their internal fund FRM.

Clariden Bank

Antonio Garcia del Rio

Daniel Roy Joanes. Met and had lunch with three bankers, very familiar with Sentry. That have also some of them been nvestors in Balboa, and recently departed. All are familiar with the internal Fund of Funds effort and talks w/FGG on FFTW, which is where we concentrated our efforts. Put 2mm Sentry requirement on the table, which we are negotiating as are also analysing FFTW subscription. Antonio introduced us to Daniel who works on the Portuguese market and wanted to buy Sentry. We also introduced GMO and the Masters Fund. They showed interest for these products.

08/29/02 in Geneva:

Equitas

CONFIDENTIAL

Charles Ioas. He is Director in this Institution that belongs to Rothschild Zurich. They need to have an approval from Rothschild Zurich to invest in our Fund. So Rothschild was going to take care about approving our funds doing a due-diligence in London and New York. We gave him US\$ 300.000 in Sentry. We asked him if he knew the result of the due-diligence that

2

10-04330-lgb Doc 331-64 Filed 06/24/25 Entered 06/24/25 22:30:48 Exhibit 62 Pg 4 of 6

Rothschild did on our products which he was ignoring. He sells for the moment mostly the FoF Nemrod that belongs to Rothschild. We also introduced GMO.

Partners Advisers

Jerome Muller who I have visited with Richard and Dave Muller told me that they might go to New York in the next months and see FFTW. Luc Estenne, the Managing Partner of this firm is in New York for the moment and we ask him through Jerome if he is interested to organize a meeting. If there is interest, he will come back to us. Also we introduced GMO to them. They think that FFTW is doing well.

Forvest Trust

Jan Buess is the General Manager of a small FoF that has been created 6 months ago. They have US\$ 3 MM in this FoF which only invests in Long-Short Strategy for the moment. His idea is te add another strategy and FFTW is a fund that he is considering. He has been following the fund since 6 months and is willing to do something with us. GMO besides FFTW represents interesting alternative as diversifies existing Long/ Short strategies due to its Quant style and Market Neutral philosophy. He has to convince his colleagues.

Banque Vontobel

Ignacio Jimenez who is an ex Private Banker at Barclays has communicated a lack of interest in their Absolute Return Strategy Fund (which incorporates 50% of Sentry). This FoF is up only 2% this year. We introduced GMO and the Masters Fund which he showed interest for.

Forum Finance Group

Erick Zanker explained us that FFTW is in the list of 6 funds that are approved for their clients. He is waiting for better merkets before proposing this product to his clients because he thinks that hedge funds are really interesting when the market is flat.

08/30/02 in Geneva:

Van Daalen

Javier Gonzalez Florenzano was interested in GMO. We also spoke about FFTW and we will keep him informed about the evolution of our funds. Principal JGF, has been adamant to doing business with FGG, since 2000. This after sudden sale of Sentry, due to negative opinion of Madoff. Also perception that we had not evolved beyond this fund. Results of the visit; recognized interest for FFTW, opinion which is apparently supported by John rout,(Barany-Monaco) external consultant, GMO would also be evaluated. Introduced new analyst called Christian Jauch and gave us the name of Farid Saffar of Asset Consult, as someone he had referred to FFTW. On this last two need to include in our Schedule A, and make sure they get on our list.

Barclays

Juan Carlos Aguilar + Blaise Gillioz + 5 people: meeting went very well with high level of interest for each one of our funds, FFTW, GMO and the Masters Fund. Further interest possible but if get final approval from their gatekkeper, which is Michael Green of Barclay's UK. Comunicated with Adam Horne, await news of what hopefully will be a timely approval of the funds, so the bankers can invest. Meanwhile 3mm of Sentry allocation order came in and we accepted it to motivate them to invest in our other funds. We had questions about the 95-5 Sentry Allocation, which was not very clear to them.

3

CONFIDENTIAL FGANW005076464

10-04330-lgb Doc 331-64 Filed 06/24/25 Entered 06/24/25 22:30:48 Exhibit 62 Pg 5 of 6

AD Capital

Alejandro Dahlhaus is currently invested in Sentry & FFTW but could invest more and GMO, as well. Liked market neutral philosophy and possible fit for this strategy within his rather mostly cash and fixed income portfolios. Solicited our view on Bridport, long Bond recomendations.

EC Venture Capital

Andre Walkowicz

First call but had very strong introduction from ex colleague at Credit Suisse, which led to good open dialogue. Also had Russian client sit in on thecall, as working on developing this and other Eastern European markets. All funds were of interest, and offered to conduct due diligence. Funds under management currently 200mm, with existing investment in MultiStrategy fund of funds.

09/02/02 in Geneva:

Banque Sarasin

Ross Hanson: second meeting with him. He has demand for hedge funds in his clients, so he wants to know more about our products. I presented him GMO and the Masters Fund. He likes our products and might start promoting them to his clients.

Calypso Asset Management

Julio Morin

Edouard de l'Espee: They are Adam's client and we just supported his relationship introducing GMO and the Masters Fund. They are clients in FIF.

Genevalor

Christophe Velay. This firm is part of Hermes Fund and is specialized in the Market Neutral strategy. They are investors in Whiteford and have a long relationship with FGG. We only presented GMO to them in order to support the existing relationship. Contact made with Cristophe Velay recently incorporated from Merrill, whom agreed to the meeting, on the strength, of a mutual friends referral. Hermes was the contact we had been provided, so this was the name we sent into NY for clearance, which went through the system with an OK response. From the looks of it I jumped the gun on this one as there is evidently a preexisting relationship with FGG, but confident no harm done as showed alot of interest for our funds.

Unifund

Amanuel Mazengia: last time we saw him (2 months ago), he showed a lot of interest in our products and wanted to see how we could work on a US\$ 50,000,000 ticket with Sentry allocation. But this time he tolsd us that our funds are not showing enough performance. They look more for a 40% year performance, but more volatile. We told him that we were looking for low volatility in our funds.

Banque Mirabaud

Etienne d'Arenberg

Alain Geier

Aurelie Capon: They are active in Hedge Funds since 25 years mostly in Long Short and Macro. We make them a general presentation of FGG and an extensive presentation on FFTW and GMO. They liked them very much. We will keep them informed.

Optimal

Manuel Echeverria: He listened to the GMO presentation and told us that he moight ear the conf. call about GMO.

4

CONFIDENTIAL FGANW005076465
FG-05223994

10-04330-lgb Doc 331-64 Filed 06/24/25 Entered 06/24/25 22:30:48 Exhibit 62 Pg 6 of 6

09/03/02 in Geneva:

Optifin

Yves Bryde

Andre Baer: introduction from Morgan Stanley proved to be an interesting call as have 500mm in hedge funds, and no FGG funds, since where invested in Monroe. Written to Andres P. on this account as disclosed pre-existing contact of his going back to his Littlestone days, also copied JT, as question of recomencing coverage of the account surfaced. Interest for NGA and other higher Beta funds most notable.

Banque Barings

George Gutmans: knows FGG, might buy Sentry for his clients with another of our product. Will follow up with him.

Best Regards,

Stéphane Muûls Fairfield Greenwich Group stephane@fggus.com Tel: +34 91 578 1900 Fax: +34 91 577 30 43

Mobile: +34 639 21 90 21

Change of Address

Please note our new address as of August 5, 2002:

919 Third Avenue 11th Floor New York, NY 10022

Telephone and Telefax numbers remain the same.

DISCLAIMER

This e-mail message,including any attachments, is intended only for the persons to whom it is addressed,and may contain confidential information. Any use, distribution, modification, copying or disclosure by any other person is strictly prohibited. If you have received this message in error please notify the sender by return e-mail and delete this message from your computer. Any data or views contained herein is based upon information available to us at this date and is subject to change without notice.